Background Drug-resistant epilepsy affects about one-third of children with epilepsy and is associated with high costs to the healthcare system, yet the cost effectiveness of most treatments is unclear. Use of cannabis-based products for epilepsy is increasing, and the cost effectiveness of such strategies relative to conventional pharmacologic treatments must be considered. Objective The objective of this systematic review was to identify economic evaluations of cannabis-based treatments for pediatric drug-resistant epilepsy. We also sought to identify and appraise decision models that have been used in economic evaluations of pharmacologic treatments (i.e., antiepileptic drugs) in this population. Methods Electronic searches of MEDLINE, EMBASE, and the Cochrane library, as well as a targeted grey literature search, were undertaken (11 June 2018). Model-based full economic evaluations involving cannabis-based treatments or pharmacologic treatments for drug-resistant epilepsy in children were eligible for inclusion. Two independent reviewers selected studies for inclusion, and study quality was assessed by use of the Drummond and Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklists. Study findings, as well as model characteristics, are narratively summarized. Results Nine economic evaluations involving children with drug-resistant epilepsy were identified; however, none involved cannabis-based treatments. All studies involved pharmacologic treatments compared with other pharmacologic treatments or non-pharmacologic treatments (i.e., ketogenic diet, epilepsy surgery, vagus nerve stimulation). Few studies have assessed the cost effectiveness of pharmacologic treatments in specific drug-resistant epilepsy syndromes, including Dravet and LennoxGastaut syndromes. Five included studies involved use of Markov models with a similar structure (i.e., health states based on seizure frequency relative to baseline). There was a wide range of methodological quality, and few studies fully addressed context-specific issues such as weight gain and treatment switching. Conclusion Whether cannabis-based treatments for pediatric drug-resistant epilepsy represent good value for money has yet to be investigated. Economic evaluations of such treatments are needed and should address issues of particular importance in pediatric epilepsy, including weight gain over time, switching or discontinuation of treatments, effectiveness of interventions and comparators, and long-term effectiveness beyond the duration of available clinical studies. PROSPERO Registration CRD42018099591. 
Introduction
Epilepsy is a chronic neurologic disorder that affects about 50 million people worldwide [1] . The goal of epilepsy treatment is to reduce seizures and improve quality of life with minimal adverse effects [2] . Although most people with epilepsy respond well to pharmacologic treatments, about one-third have a drug-resistant form [3] (failure of two or more adequate trials of antiepileptic drugs [AEDs] [4] ). The consequences of drug-resistant epilepsy, especially among children, are severe, including cognitive delay, behavioral problems, autism, poor quality of life, and an increased risk of death [5] [6] [7] . Children with drug-resistant epilepsy use more healthcare resources than those whose seizures are controlled [8, 9] , contributing high costs to the healthcare system [10, 11] .
There are multiple types of drug-resistant epilepsy, e.g., Dravet syndrome and Lennox-Gastaut syndrome, each with individual seizure profiles. As such, there is no one standard of care [12] , and treatment options include both pharmacologic (e.g., AEDs) and non-pharmacologic interventions (e.g., epilepsy surgery, ketogenic diet [KD] , vagus nerve stimulation [VNS] ). Parents of children with epilepsy also report use of complementary and alternative medicines [13] , including cannabis-based treatments, after failure of conventional AEDs to control seizures [14] , and recent clinical studies suggest that some cannabis-based treatments may reduce seizures among children with drug-resistant epilepsy [15] [16] [17] [18] .
In this systematic review, we sought to identify and appraise economic evaluations of cannabis-based treatments for drug-resistant epilepsy in children. We also sought to identify decision models that have been used in economic evaluations of pharmacologic treatments in this population, in order to inform the development of a de novo cost-utility analysis of cannabis-based treatments for Dravet syndrome.
Methods
The systematic review protocol was registered in PROS-PERO (registration no. CRD42018099591) and published [19] . The focus of this paper is economic evaluations of cannabis-based products and decision models that have been used to evaluate the cost effectiveness of pharmacologic treatments for drug-resistant epilepsy in children. This report follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Electronic Supplementary Material [ESM] Appendix 1) [20] . All screening and data extraction were performed using DistillerSR (Evidence Partners, Ottawa, ONT, Canada).
Eligibility Criteria
We included studies that met the criteria outlined in Sects. 2.1.1-2.1.4.
Population
Children aged less than 19 years with drug-resistant epilepsy, according to the International League Against Epilepsy (ILAE) definition (failure of two or more adequate trials of AEDs), were included [4] . Because few studies reported use of a definition of drug-resistant epilepsy, we also included those that described the target population as having "resistant", "refractory", or "intractable" epilepsy, focused on specific drug-resistant epilepsy syndromes (e.g., Dravet syndrome, Lennox Gastaut syndrome), or involved interventions intended to treat drug-resistant epilepsy (i.e., KD, epilepsy surgery, VNS).
Interventions and Comparators
We included studies involving any form of cannabis-based treatment (e.g., cannabidiol) compared with any pharmacologic (i.e., AEDs) or non-pharmacologic treatment (i.e., KD, epilepsy surgery, VNS) intended to treat drug-resistant epilepsy. In order to appraise decision models that have been used in this population, we also included studies that compared pharmacologic treatments with other pharmacologic treatments or non-pharmacologic treatments. Economic evaluations that compared non-pharmacologic interventions with other non-pharmacologic interventions were beyond the scope of this review.
Outcomes
Outcomes of interest were total and incremental costs, including direct, indirect (i.e., productivity costs), and drugrelated costs; total and incremental quality-adjusted lifeyears (QALYs); and incremental cost-effectiveness ratios (ICERs). Additionally, outcomes of interest from Markov model-based analyses were model structure (e.g., description of the included health states, horizon, cycle length) and model inputs (i.e., resource use [e.g., number of neurologist visits, admission to hospital, visits to the emergency department], utility values).
Study Designs
We included model-based full economic evaluations (i.e., cost-utility analysis, cost-effectiveness analysis, cost-benefit analysis, cost-minimization analysis) and health technology assessments that include a full economic evaluation involving a decision model. Stand-alone resource utilization and utility studies were not included in this analysis.
Search Strategy and Study Selection
Using the OVID platform, we searched Ovid MEDLINE, including Epub Ahead of Print and In-Process & Other Non-Indexed Citations, EMBASE Classic and EMBASE, as well as the Cochrane Library on Wiley, from inception to 11 June 2018. Search strategies were adjusted across databases and used a combination of controlled vocabulary (e.g., "Epilepsy," "Costs and Cost Analysis," "Quality of Life") and keywords (e.g., "seizure," "cost," "QALY"). The strategy (ESM Appendix 2) was peer-reviewed by use of the Peer Review of Electronic Search Strategies (PRESS) Checklist [21] . A targeted grey literature search was performed by searching relevant economic websites and databases included in the Canadian Agency for Drugs and Technologies in Health's (CADTH) Grey Matters [22] . The title and abstract of each identified record were screened by two independent reviewers (JE, SVK), and the full text of any record deemed potentially relevant was examined in duplicate (JE, DC). We excluded conference abstracts and nonEnglish-language records. Disagreements were resolved by discussion.
Risk of Bias and Quality of the Evidence
Two independent reviewers (JE, DC) evaluated the quality of included economic evaluations by use of the tenitem Drummond checklist [22] and the 24-item Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist [23] . For both checklists, items were graded as 'yes,' 'no,' or 'not applicable.' The Drummond checklist assesses whether appropriate methodology was used in the conduct of the economic evaluation and evaluates the validity of the results, while the CHEERS checklist focuses on issues related to reporting. Because a study authored by JE and DC was among the included studies, a third reviewer (SVK) evaluated the quality of this study. Disagreements were resolved by discussion.
Both the CHEERS and Drummond checklists are generic instruments and may not identify context-specific issues that are important to specific decision problems [24] . We identified an additional five issues pertinent to economic evaluations in pediatric drug-resistant epilepsy: first, we considered whether weight gain had been incorporated into the decision model, if appropriate (i.e., time horizon longer than 1 year). Given that pharmacologic treatments are frequently dosed based on patient weight, and that a child's weight may increase considerably over the analysis horizon, failure to consider weight gain may be a source of bias. Second, we considered whether discontinuation or switching of treatments was addressed. Changing treatments is common among children with drug-resistant epilepsy, with new treatments added or current treatments discontinued in an attempt to control seizures. Third, we considered whether the assumptions made about effectiveness were unbiased across all study treatments. Fourth, we assessed whether all relevant clinical data were incorporated into the model. Finally, we assessed assumptions made about the effectiveness beyond the duration of existing clinical studies.
Data Extraction and Synthesis
Study data were extracted by one author (JE) and verified for completeness and accuracy by a second reviewer (DC), with disagreements resolved by discussion. We extracted study characteristics, including design, location, modeling method (i.e., decision tree or Markov model), and intervention/comparator details. Study findings (e.g., ICERs) as well as study and population characteristics, model inputs, and quality are summarized descriptively. To facilitate comparison between studies, all costs are expressed in 2018 Canadian dollars ($Can) ($Can1 = $US0.7721, €0.6538). If necessary, costs were converted to Canadian dollars using purchasing power parity for the year of the study and then adjusted to 2018 based on the Bank of Canada Inflation calculator. Data are reported separately by drug-resistant epilepsy syndrome, where available.
Results

Search Results
The literature search yielded 7460 unique records (Fig. 1 ). Of these, 463 were reviewed for eligibility in full-text format. Ten economic evaluations met the inclusion criteria (ESM Appendix 3); however, it was unclear whether one study [25] was a model-or trial-based evaluation and it was not included in the evidence summary. Thus, the evidence base for this review comprised nine full economic evaluations based on decision models involving treatments for drug-resistant epilepsy in children [26] [27] [28] [29] [30] [31] [32] [33] [34] . No studies assessed the cost effectiveness of cannabis-based treatments for pediatric drug-resistant epilepsy.
General Characteristics of Included Studies
Each of the nine included economic evaluations evaluated the cost effectiveness of pharmacologic treatments for drugresistant epilepsy compared with other pharmacologic treatments (four studies [26, 28, 30, 33] ) or with VNS, KD, or epilepsy surgery (one study [29] ) (Table 1 ). In the remaining four studies [27, 31, 32, 34] , pharmacologic treatments were grouped as 'care as usual' or 'medical management'; the pharmacologic treatments included in these 'usual care' regimens were not well-described (e.g., did not specify which AEDs were involved in the treatments). The included studies comprised five cost-utility analyses [27-29, 32, 33] , assessing costs per QALY gained, while four studies [26, 30, 31, 34] assessed cost effectiveness by use of alternative health outcomes, with one study each assessing health gains as percentage of successfully treated patients (defined as > 50% seizure reduction) [26] , percentage of patients with seizures controlled (not defined) [30] , percentage of seizures reduced compared with baseline [34] , or seizure freedom [31] .
Four studies targeted specific patient populations, including Dravet syndrome (one study [28] ), Lennox Gastaut syndrome (two studies [26, 33] ), and tuberous sclerosis complex (TSC; one study [29] ), while the remaining studies targeted drug-resistant epilepsy in general [27, [30] [31] [32] 34] . The studies were conducted between 1999 and 2018, and the majority were performed in Canada (four studies [27, 28, 31, 34] ) and the UK (two studies [26, 33] ), with one study each from the USA [29] , Iran [30] , and The Netherlands [32] . Most studies were undertaken from the perspective of the healthcare system (seven studies [26] [27] [28] [29] [32] [33] [34] ). One study [31] adopted a government perspective; however, the costs included were related to a societal perspective (direct costs, parent productivity loss, social or community living costs). Finally, the perspective of one study was described as "patient" but was limited to drug-related costs (drug-budget perspective) [30] . Five economic evaluations involved a Markov model [26-28, 32, 33] , while the remainder involved a decision tree [29] [30] [31] 34] . Of the studies that involved a decision tree, two compared pharmacologic treatment to epilepsy surgery [31, 34] , one compared pharmacologic treatment (carbamazepine) to KD, VNS, or epilepsy surgery [29] , and one compared various pharmacologic treatments over a 3-month horizon [30] . Two studies assessed outcomes in terms of seizure reductions through the Engel criteria [29, 34] , whilst another dichotomized the outcomes as seizure control or no control [30] . For the other study using a decision tree, it was not possible to determine the outcomes modeled [31] . The included economic evaluations were primarily funded by non-industry sources or had no funding (five studies [27] [28] [29] [30] 32] ; 56%), while two studies (22%) reported industry funding [26, 33] and two (22%) did not report the funding source [31, 34] . 
Critical Appraisal
There was a wide range in the methodologic and reporting quality of the included studies, ranging from 4 to 10 points on the Drummond checklist (of 10 points; Fig. 2 ) and 7 to 22 points on the CHEERS checklist (of 24 points; ESM Appendix 4). In general, most studies (> 75%) specified the decision problem, target population, and adopted perspective, and described the decision model and assumptions; however, few provided sufficient description of the competing [28, 32] . Among the included cost-utility analyses, few studies (40%) described the population and methods used to elicit preferences for the health states. Although most authors addressed the limitations of their analyses, few addressed issues of concern such as generalizability of the findings to other jurisdictions or across epilepsy syndromes. Most of the included studies performed sensitivity analyses; however, the type and parameters tested varied across studies ( Table 2 ). All studies assessed the impact of at least one alternative model input, including costs, utilities, and/or effectiveness estimates, through deterministic or probabilistic sensitivity analyses or scenario analyses; fewer studies assessed the impact of alternative structural assumptions [26-28, 31, 33] .
Context-Specific Issues
Weight Gain Of the included studies, only one considered the impact of increasing patient weight on the ICER. In sensitivity analyses, Elliott et al. [28] varied the starting age of the patient cohort, incorporating child weight by use of the World Health Organization's weight-for-age 50th percentile value [35] . The remaining studies assumed a fixed weight over the analysis horizon or did not report assumptions about patient weight. Although the dose of AEDs may not be adjusted at every clinical encounter, over time the weight-based dose would be expected to increase as a child ages and increases in weight. Among the decision models included in this review, the analysis horizon ranged from 3 to 20 years, and the failure to consider weight gain may underestimate total drug costs, especially for studies with a horizon longer than 10 years.
Treatment Discontinuation or Switching
Four studies addressed switching treatments during the analysis horizon [26, 28, 32, 33] , while the remaining studies assumed that no changes occurred [29, 30, 34] or did not report whether changes were permitted [27, 31] . Elliott et al. [28] assumed that patients with Dravet syndrome whose seizures did not respond to adjunctive stiripentol treatment within the first 6 months of treatment would discontinue stiripentol and continue on clobazam and valproate alone. Similarly, both Benedict et al. [26] and Verdian and Yi [33] assumed that patients with Lennox-Gastaut syndrome whose seizures were not adequately controlled by rufinamide, topiramate, or lamotrigine would switch to "standard treatment" (the patients' AEDs taken at baseline) [26] or to the mix of AEDs used in the placebo arm of a clinical trial [33] ; in both cases, the specific AEDs that made up the standard treatment arm were not described. Finally, de Kinderen et al. [32] assumed that patients who withdrew from the KD would return to a normal diet, while patients with a VNS could have it switched off or removed; however, no changes were made to AED treatments in the "care as usual" group.
Among studies that did not permit switching between treatments, Gharibnaseri et al. [30] considered remaining on a treatment regimen for the 3 months' duration of the analysis as part of their effectiveness outcome, while Widjaja et al. [34] assumed that medication type and dose would remain constant for the first year following epilepsy surgery; whether patients in the medical management arm could switch AEDs was not reported. Finally, Fallah et al. [29] assumed that patients would stay on a chosen treatment for the 5-year study duration.
Effectiveness of Usual Care
In six studies [26, 27, [31] [32] [33] [34] , pharmacologic treatments were included as "usual care", "standard treatment", or "medical management" without detailed description of the AEDs included in the treatment regimens, and one study [30] compared individual "newer" AEDs to older AEDs as a group (including carbamazepine, ethosuximide, phenytoin, phenobarbital, primidone, and valproate). Two studies [30, 34] derived effectiveness estimates from retrospective reviews of clinical data at single centers, while two studies [26, 32] derived estimates of the effectiveness of usual pharmacologic care from the control arms of RCTs. Other studies assumed that patients in the medical treatment arm would not improve (i.e., continue to have inadequately controlled seizures) [27] , assumed a "spontaneous remission rate" of 10% [31] , or did not describe assumptions related to the efficacy of standard medical care [33] . (1) well-defined question; (2) well-described competing alternatives; (3) established effectiveness; (4) important and relevant costs and consequences identified; (5) measurement accurately performed; (6) costs and consequences valued credibility; (7) discounting; (8) incremental analysis performed; (9) allowance made for uncertainty; and (10) all items of concern to users discussed
The comparators in two studies were specific AED regimens [28, 29] . Elliott et al. [28] compared adjunctive stiripentol to a regimen of clobazam and valproate alone in children with Dravet syndrome, while Fallah et al. [29] compared carbamazepine to KD, VNS, or epilepsy surgery in children with TSC. Elliott et al. [28] estimated the effectiveness of clobazam and valproate from a pooled analysis of the control arms of two RCTs [36, 37] , while the effectiveness estimate for carbamazepine used by Fallah et al. [29] was derived from a retrospective review of clinical data for children with TSC at a single center [38] . Clinical Effectiveness In general, meta-analyses of randomized controlled trials (RCTs) involving head-to-head comparisons of the competing interventions are considered to provide the highest level of evidence to inform decision models [39] . However, because of the rare nature of some drug-resistant epilepsy syndromes, and because few RCTs have been performed in some populations [40] , we considered the source of data used to derive effectiveness estimates and how studies addressed a lack of RCTs, if applicable. Of the nine included studies, three used data derived from RCTs to inform their model [26, 32, 33] , either by pairwise [32] or indirect treatment comparison pooling [26, 33] . One study [28] derived effectiveness estimates by use of individual patient data from a multicenter, prospective observational cohort [41] , despite the availability of RCT data, due to a longer follow-up duration in the observational study than in the RCTs. Three studies [27, 30, 34] used data from retrospective observational studies, due to a lack of RCTs for the model comparators, while two studies [29, 31] did not provide sufficient information about the source of the effectiveness data.
Long-Term Clinical Effectiveness
Among seven of the included decision models [26] [27] [28] [29] [31] [32] [33] , the analysis horizon was longer than the duration of the studies used to estimate effectiveness. As such, assumptions were required about the continuation of effect beyond the available data. Four studies [26, 28, 29, 33] assumed that the effectiveness (i.e., transition probabilities) would be consistent beyond the observed duration, assuming no waning of treatment effect. In contrast, one study [32] assumed that there would be no change to seizure status after the first 24 months of treatment, such that a patient in the seizure-free state would remain in that state for the remainder of the 5-year horizon. One study [27] assumed that all patients in the medical management arm would remain drug refractory (i.e., no improvement) over the entire 20-year horizon, while patients in the other comparator arms would continue to move through model states based on transition probabilities from the first year of treatment. One study [31] did not report assumptions about maintenance of effect beyond the available data, despite a 25-year horizon.
Decision Model Characteristics
Of the included studies, five involved use of a Markov model (Table 3) [26-28, 32, 33] . Each model involved three health states related to the frequency of seizures relative to a baseline period; death was the final absorbing state in each model. Each model included a state in which patients experienced no improvement (one study [27] ) or limited improvement (< 50% reduction in seizures; four studies [26, 28, 32, 33] ). The models used in three studies [26, 27, 32] included a seizure-free state, while two studies [26, 33] used a > 75% seizure reduction as the state with greatest improvement. Most models involved a 3-month cycle (three studies [26, 32, 33] ), while one study used a 1-month [28] and another a 1-year cycle [27] . No study justified the chosen cycle length. The analysis horizon ranged from 12 months to 20 years, and most studies provided justification for the chosen time horizon based on the availability of data (three studies [26, 32, 33] ) or transition to adult care (one study [28] ). Four studies [26] [27] [28] 33] tested the impact of alternative horizons in sensitivity analyses.
Decision Model Inputs
Costs
Each study included at least some costs directly related to the provision of healthcare (Table 4) . One study included only drug costs in their evaluation [30] , without consideration of other costs or resources that may differ between competing treatments, while one study [32] assumed that drug costs would be equivalent between competing treatments (pharmacologic treatment alone or in combination with KD or VNS), thus omitting drug costs from their analysis. Most studies included costs related to visits to a neurologist or epileptiologist (78%), while fewer studies included visits to a primary care physician (33%) or emergency department (33%) ( Table 4 ). Admission to hospital or an intensive care unit was included in 56% and 22% of analyses, respectively; one study [28] included costs related to ambulance transfer to hospital. Nursing-related costs were included in 44% of studies, although additional studies may have captured nursing costs as part of hospital-related costs. Diagnostic procedures were included in 22% of studies, and professional services (e.g., learning disability specialist, clinical psychologist) were included in 33% of studies.
One study [31] included indirect costs as part of their analysis, which was described as a governmental perspective but was more broad, including parental productivity losses as well as costs related to social or community living. No studies included costs related to patient productivity losses, either as losses during childhood or future losses during adulthood.
Utility Values
The cost-utility analyses included in this review [27-29, 32, 33] used health state utility values derived from three studies, reported in three conference abstracts [42] [43] [44] and one full publication [45] . Of these, two studies [42, 43, 45 ] assessed utilities among adults with epilepsy: in one study [45] , patients in each health state (ranging from "suboptimal" seizure control to seizure free) were asked how much time they would be willing to give up to live their remaining years in "excellent health," while one study [42, 43] assessed EQ-5D scores among adults with recurrent seizures after 6 months of adjunctive AED treatment. One study [44] assessed preferences for states related to LennoxGastaut syndrome, elicited by time trade-off from members of the general population. None of the included cost-utility [26] 3 years 3 months Costs: 3.5%; benefits not discounted < 50% seizure reduction from baseline 50-75% reduction > 75% reduction Death Verdian and Yi, 2010 [33] 3 years 3 months Costs and benefits: 3.5% < 50% seizure reduction 50% to < 75% reduction 75% reduction from baseline Death analyses considered health effects on caregivers or other family members.
Study Findings
Cannabis-Based Treatments
No completed economic evaluations of cannabis-based treatments for pediatric drug-resistant epilepsy were located. We identified one in-progress cost-effectiveness analysis of cannabidiol for seizures associated with Dravet and Lennox Gastaut syndromes; no results are available at this time [46] .
Pharmacologic Treatments
Nine studies of pharmacologic treatments for pediatric drugresistant epilepsy were included in this review. The main outcomes, costs, and ICERs are summarized in Table 5 . We summarize the findings separately by epilepsy syndrome, where possible.
Dravet Syndrome One study [28] assessed the cost effectiveness of adjunctive stiripentol compared with clobazam and valproate in children with Dravet syndrome whose seizures had not previously responded to clobazam and valproate. From the perspective of the Canadian public healthcare system, adjunctive use of stiripentol was both more effective and more costly than use of clobazam and valproate alone, resulting in an incremental cost of $Can154,336 per QALY gained with stiripentol treatment.
Lennox-Gastaut Syndrome
Two studies [26, 33] assessed the cost effectiveness of adjunctive rufinamide, topiramate, or lamotrigine compared with standard treatment with older AEDs among children with Lennox-Gastaut syndrome from the perspective of the UK healthcare system. For treatment of drop seizures, Benedict et al. [26] estimated that rufinamide, topiramate, and lamotrigine were each less costly and more effective than standard therapy with older AEDs. Compared with topiramate, rufinamide was associated with an ICER of $Can132 for each 1% increase in successfully treated patients (drop seizures reduced by at least 50%), while lamotrigine and standard treatment were dominated. For total seizures, standard treatment and topiramate were dominated by lamotrigine, and rufinamide was associated with an ICER of $Can5526 for each 1% increase in successfully treated patients. Similarly, Verdian and Yi [33] estimated that the addition of rufinamide to a background of standard AEDs would be more costly than the addition of either topiramate or lamotrigine, with an estimated ICER of $Can52,955 compared with topiramate and $Can399,214 compared with lamotrigine per QALY gained.
Tuberous Sclerosis Complex One study [29] assessed the cost effectiveness of adjunctive carbamazepine, KD, VNS implantation, and resective surgery for the treatment of drugresistant epilepsy in children with TSC whose seizures had not responded to two previous AEDs. Compared to adding carbamazepine, KD and VNS implantation were both more costly and less effective (dominated), while resective surgery was associated with an incremental cost of $Can369,712 per QALY gained.
Unspecified Types of Drug-Resistant Epilepsy
Five studies assessed the cost effectiveness of treatments for drugresistant epilepsy in children without specifying a specific syndrome [27, [30] [31] [32] 34] . One study [30] compared the addition of newer AEDs (gabapentin, levetiracetam, lamotrigine, oxcarbazepine, topiramate, vigabatrin, zonisamide) to a regimen including older AEDs (carbamazepine, ethosuximide, phenytoin, phenobarbital, primidone, valproate), considering only costs related to AEDs: lamotrigine, oxcarbazepine, topiramate, and vigabatrin were associated with ICERs of $Can744, $Can898, $Can2458, and $Can5123 per patient with controlled seizures, respectively; while gabapentin, levetiracetam and zonisamide were dominated by conventional AEDs.
The remaining four studies [27, 31, 32, 34] included pharmacologic treatments as comparators to KD, VNS implantation, or surgery (Table 1) ; each of these studies grouped pharmacologic treatments as "medical management" or "care as usual" without fully describing the AED regimens used. Among these studies, pharmacologic treatment was less effective and less costly than surgery [27, 34] , KD [32] , and VNS [32] . Compared with medical management, surgery was associated with an ICER of $Can432 per 1% reduction in seizures [34] , and KD and VNS were associated with an ICER of $Can517,306 and $Can955,979, respectively, per QALY gained [32] (Table 6 ). One study, undertaken from a government perspective, reported that surgery was less costly and more "cost-efficient" than pharmacologic treatment; however, effectiveness data and the ICER were not reported [31] .
Discussion
The first objective of this review was to identify economic evaluations of cannabis-based treatments for drug-resistant epilepsy in children; however, no such completed studies were located. One ongoing health technology assessment of cannabidiol for the treatment of Lennox-Gastaut and Dravet syndromes was located, with results expected in late 2019 [46] . A 2018 systematic review of cannabis-based treatments for chronic illnesses in adults similarly found no economic evaluations of such treatments for epilepsy [47] . Our second objective was to identify and appraise decision models that had been used in full economic evaluations of pharmacologic treatments for children with drug-resistant epilepsy in order to inform a subsequent de novo cost-utility analysis. Our findings highlight a lack of studies in this population, with a total of nine eligible studies, including two in Lennox-Gastaut syndrome [26, 33] and one each in Dravet syndrome [28] and TSC [29] . Because of important differences in patient populations, modelling approaches and assumptions, and study comparators, it is difficult to compare cost effectiveness across studies and interventions. Furthermore, we observed wide variation in the quality of published economic evaluations in this clinical area; decision makers should consider the study quality and its relevance to clinical practice in their jurisdiction when evaluating whether an intervention is cost effective.
There were important differences in methodologies among the included studies, including the modeling approach used (i.e., decision tree, Markov model), model assumptions, and included costs. However, among studies that involved use of a Markov model, the health states were relatively consistent, despite differences in cycle length and analysis horizons. Few studies considered issues specific to pediatric epilepsy, including weight gain and changing treatments during the analysis horizon. As well, although most studies were undertaken from a healthcare perspective, the resources included varied widely between studies. Most included visits to a neurologist or epileptologist (78%); however, few studies included visits to a general practitioner, emergency department, or admission to hospital (33-56%) . This is an important consideration because costs related to hospitalization account for a large portion of direct costs in some drug-resistant epilepsy syndromes and may vary depending on intervention [48] ; as such, a failure to include such costs may introduce bias into the economic evaluation. Recent studies have reported costs associated with some drug-resistant epilepsy syndromes, including Dravet syndrome [49, 50] , which may help to inform future economic evaluations in this population.
Healthcare decision makers will soon be faced with the decision of whether to reimburse cannabis-based products through public formularies. The first pharmaceutical-grade cannabidiol product, Epidiolex ® (GW Pharmaceuticals, Cambridge, UK), recently received approval from the US Food and Drug Administration (FDA) [51] , and cannabis producers in other jurisdictions have developed high-concentration cannabidiol products that have shown promise in clinical studies [52] . In order to evaluate whether such interventions represent good value for money compared to currently available treatments, it is imperative that both the costs and benefits of both the new interventions as well as the currently existing treatments are considered. In our review, we found that cost effectiveness has been evaluated for few of the currently available pharmacologic treatments for drug-resistant epilepsy in children, despite being listed on public formularies. This finding is consistent with a 2017 systematic review [53] , which identified few economic evaluations of treatments drug-resistant epilepsy in children.
Drug-resistant epilepsy affects an estimated 16 million people worldwide. Despite this, some drug-resistant epilepsy syndromes are individually rare (e.g., Dravet syndrome, Lennox-Gastaut syndrome), and there are limited clinical trials to support the efficacy of most treatments, especially among children [54, 55] . Some authors have argued that treatments for rare diseases should not be held to the same standards as drugs to treat common diseases, instead following the 
Context-specific issues
Weight gain Drug dosages are frequently based on patient weight; failure to consider weight gain may underestimate drug costs For studies with an analysis horizon longer than 1 year, patient weight gain should be considered. This may be most relevant for studies involving young children and those with uncontrolled seizures Treatment discontinuation/switching Patients with drug-resistant epilepsy whose seizures do not respond to treatment may discontinue the intervention or switch to an alternative treatment Medication switches should be considered, including any costs associated with switching. The duration of treatment before discontinuation or switching should be specified and justified
Effectiveness of usual care 'Usual care' may vary by jurisdiction and epilepsy syndrome, and insufficient description of usual care as a comparator does not allow decision makers to assess relevance to their jurisdiction The interventions that comprise 'usual care' should be explicitly described.
Any assumptions about the effectiveness of usual care should be justified
Clinical effectiveness There may be limited information about the clinical effectiveness of interventions for drug-resistant epilepsy, owing to the rarity of some individual syndromes Choice of data should be based on fitness for purpose, credibility, and consistency; use of a hierarchy [39] may be useful in selecting data
Long-term effectiveness Decision analyses with a long-term horizon may require assumptions about the maintenance of effect beyond the duration of treatment reported in available clinical studies
Assumptions about the effectiveness of interventions beyond the duration of clinical observation should be explicitly reported rule of rescue without consideration of the cost per benefit gained [56] . However, a recent survey found that Canadians place more value on drug effectiveness and safety, as well as the ability to improve quality and quantity of life, than rarity of the target condition [57] . Because of this, as well as high opportunity costs, drugs to treat rare diseases, including drug-resistant epilepsy syndromes, should be rigorously evaluated and must show good value for money through cost-effectiveness evaluations. In Table 6 , we provide recommendations for future economic evaluations in this area.
Strengths and Limitations
We undertook a systematic review of the published and grey literature to identify relevant economic evaluations, and the protocol was registered a priori. However, several limitations should be considered. First, the review was limited to studies reported in English, which may have excluded relevant studies. Second, because we sought to identify and appraise decision models that had been used to evaluate the cost effectiveness of pharmacologic treatments for drug-resistant epilepsy, we excluded trial-based economic evaluations. Although RCTs provide important information that can be used in the context of a decision model, trial-based economic evaluations are unlikely to include all relevant comparators, have a short analysis horizon, and include costs not relevant to clinical practice [58] . Third, the included studies were of variable quality, and few adequately considered contextspecific issues, which may bias their findings. Finally, the generalizability of the findings from most of the included studies is limited, because most did not specify a specific epilepsy syndrome. Drug-resistant epilepsy is a heterogeneous population, defined based on response to AEDs [4] , not on clinical characteristics or seizure profile. Similarly, about half of the reviewed studies included pharmacologic treatments as 'care as usual' or 'medical treatment' without adequately describing the treatment regimen. However, the decision models used in such studies are likely to be generalizable across epilepsy syndromes, with inputs tailored to the specific populations and interventions of interest.
Conclusion
Although cannabis-based treatments may be effective in reducing seizures associated with drug-resistant epilepsy, the cost effectiveness of such treatments relative to other currently available treatments has yet to be investigated. Few economic evaluations of treatments for drug-resistant epilepsy have been conducted, and this review highlights areas where additional research is needed. Future studies will be improved by addressing issues of particular importance in economic evaluations of pediatric epilepsy.
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